Cardiol Therapeutics

Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. The firm is conducting clinical studies to evaluate the efficacy and safety of CardiolRx in diseases affecting the heart: a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the ARCHER trial) in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis. It is also involved in developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Proprietary formulation produces ultra-pure pharmaceutical cannabidiol (CBD) without the psychotropic effects of THC for the treatment of inflammatory heart disease Received US FDA approval to commence a Phase II/III COVID-19 trial investigating the cardioprotective properties of CardiolRx Investigational New Drug (IND) application cleared by the FDA for a Phase II international trial assessing the safety and tolerability of CardiolRx, as well as its impact on myocardial recovery in patients presenting with acute myocarditis What Cardiol Therapeutics does: Cardiol Therapeutics Inc (TSE:CRDL) (OTCQX:CRTPF) is a clinical-stage biotechnology company focused on developing innovative therapies for inflammatory heart disease. The Canadian specialty pharmaceutical company has developed a proprietary formula of ultra-pure pharmaceutical cannabidiol (CBD) that does not contain THC - less than 10 parts per million (ppm) - and consequently none of the psychotropic effects of THC.

Cardiol Therapeutics is commercializing its THC-free cannabidiol formulation to treat heart disease

Cardiol Therapeutics Inc. has announced that the US Food and Drug Administration approved its Investigational New Drug (IND) application for a Phase II trial to study the safety and tolerability of CardiolRx as well as its impact on recovery in patients with acute myocarditis.

Cardiol Therapeutics wins FDA approval for clinical trial of CardiolRx to treat patients with acute myocarditis

Oakville, Ontario--(Newsfile Corp. - August 24, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce that the U.S. Food and Drug Administration (FDA) has provided clearance to proceed with the Company's Investigational New Drug (IND) application to commence a Phase II, multi-center, double-blind, randomized, placebo-controlled trial designed to study the safety...

Cardiol Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for Phase II Clinical Trial of CardiolRx(TM) for Acute Myocarditis

NanoVibronix

Virpax Pharmaceuticals

Bit Digital, Inc

Support.com

As we begin another week, here's a look at some of the best short squeeze stocks available to investors according to research from Fintel. The post Short Squeeze Stocks: VRPX, CRDL and 3 Others Experts Think Are Ready to Pop appeared first on InvestorPlace.

Short Squeeze Stocks: VRPX, CRDL and 3 Others Experts Think Are Ready to Pop

Cardiol Therapeutics Inc. said it has received final approval from The Nasdaq Capital Market to list its common shares on NASDAQ.

Cardiol Therapeutics receives final approval to list its common shares on NASDAQ from August 10, 2021

Oakville, Ontario--(Newsfile Corp. - August 9, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, announced today that it has received final approval from The Nasdaq Capital Market LLC ("NASDAQ") to list its common shares on NASDAQ. The Company's shares will begin trading on August 10, 2021, under the symbol "CRDL".The Company's common shares will continue to...

Cardiol Therapeutics to Commence Trading on NASDAQ Under the Symbol "CRDL"

Oakville, Ontario--(Newsfile Corp. - May 12, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce the closing of its previously announced "bought deal" short form prospectus offering (the "Offering") of units of the Company ("Units") for aggregate gross proceeds of approximately $22 million.The Offering was completed by a syndicate of underwriters led by...

Cardiol Therapeutics Closes $22 Million Bought Deal Offering

News for Cardiol Therapeutics Stock (CRDL)